MDCC Molecular Devices (MM)

SUNNYVALE, Calif., Jan. 26 /PRNewswire-FirstCall/ -- Molecular Devices Corporation (NASDAQ:MDCC), a leader in innovative solutions for drug discovery and life sciences research, today announced the introduction of the Arcturus(XT) laser capture microdissection instrument. The open-architecture Arcturus(XT) system is built upon the Nikon TE2000U(R) inverted research grade microscope and combines infrared (IR) laser-enabled laser capture microdissection (LCM) and ultraviolet (UV) laser cutting in a single modular instrument, offering researchers superior speed, precision and flexibility. By utilizing the Nikon TE2000U(TM), the Arcturus(XT) is completely modular and fully upgradeable, allowing the system utility to expand as research requirements grow and microdissection technologies emerge. The Arcturus(XT) instrument employs Molecular Devices' exclusive LCM technology and, combined with the system's automated image archiving, enables researchers to maintain sample custody at all times, taking the guesswork out of microdissection. Optional high-intensity halogen illumination enables phase contrast and differential interference contrast (DIC), making the system ideal for live-cell applications. The available microscope port also enables system modification for alternate applications, with potential add-ons, such as optical trap laser tweezers, for high-precision micromanipulation of microscopic particles, or an additional camera for high-resolution imaging. The intuitive software and ergonomic user interface have been designed to make microdissection simple and straightforward. Commenting on the launch, Varshal Dave, Director of Marketing for LCM and Microarray Systems at Molecular Devices, stated, "Arcturus(XT) is the first modular, upgradeable LCM instrument with a unique infrared capture and UV laser cutting in one system. This system offers researchers the broadest scientific applicability in the microdissection market, while maintaining the ease-of-use and performance our customers have come to expect. As with all of our previous LCM instrument offerings, the Arcturus(XT) system documents the entire microdissection process from start to finish, enabling the tracking of captured samples. Furthermore, the Arcturus(XT) offers researchers additional flexibility by allowing them to utilize any type of sample preparation slide type, which is not offered with other commercial instruments. We are extremely excited about the benefits the Arcturus(XT) will provide to our microdissection customers." Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Molecular Devices' systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics, proteomics and parallel chemistry to facilitate the high-throughput and cost-effective identification and evaluation of drug candidates. Molecular Devices' solutions are based on its advanced core technologies that integrate its expertise in engineering, molecular and cell biology and chemistry. Molecular Devices enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs. This press release contains "forward-looking" statements, including statements related to the prospects for or potential customer use of the Arcturus(XT) laser capture microdissection instrument. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Molecular Devices Corporation to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of new products and their commercial acceptance, and other risks detailed from time to time in Molecular Devices' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2006. Molecular Devices Corporation does not undertake any obligation to update forward-looking statements. DATASOURCE: Molecular Devices Corporation CONTACT: Tim Harkness of Molecular Devices Corporation, +1-408-747-3533 Web site: http://www.moleculardevices.com/

Copyright